ALK protein expression in pulmonary adenocarcinoma of Tunisian patients

References

• Travis, W.D.; Brambilla, E.; Burke, A.; Marks, A.; Nicholson, A.G. Classification of Tumours of the Lung, Pleura, Thymus and Heart, 4th ed. International Agency for research on Cancer: Lyon, 2015; Ch.1, 9–84.
   Google Scholar
• Torre, L.A.; Siegel, R.L.; Jemal, A. Lung Cancer Statistics. Adv. Exp. Med. Biol. 2016, 893, 1–19.
   PubMed Web of Science ®Google Scholar
• Jemal, A.; Bray, F.; Center, M.; Ferlay, J.; Ward, E.; Forman, D. Global Cancer Statistics. CA Cancer J. Clin. 2011, 61, 69–90.
   PubMed Web of Science ®Google Scholar
• Midha, A.; Dearden, S.; McCormack, R. EGFR Mutation Incidence in Non-small Cell Lung Cancer of Adenocarcinoma Histology: A Systematic Review and Global Map by Ethnicity (mutMapII). Am. J. Cancer Res. 2015, 5(9), 2892–2911.
   PubMed Web of Science ®Google Scholar
• Nishii, T.; Yokose, T.; Miyagi, Y.; Daigo, Y.; Ito, H.; Isaka, T.; Imai, K.; Murakami, S.; Kondo, T.; Saito, H. Clinicopathological Features and EGFR Gene Mutation Status in Elderly Patients with Resected Non-small-cell Lung Cancer. BMC Cancer 2014, 14, 610.
   PubMed Web of Science ®Google Scholar
• Yanagawa, N.; Shiono, S.; Abiko, M.; Ogata, S.Y.; Sato, T.; Tamura, G. The Correlation of the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification with prognosis and EGFR mutation in lung adenocarcinoma. Ann. Thorac Surg. 2014, 98(2), 453–458.
   PubMed Web of Science ®Google Scholar
• Zhou, J.X.; Yang, H.; Deng, Q.; Gu, X.; He, P. Oncogenic Driver Mutations in Patients with Non-small-cell lung Cancer at Various Clinical Stages. Ann. Oncol. 2013, 24, 1319–1325.
   PubMed Web of Science ®Google Scholar
• Soda, M.; Choi, Y.L.; Enomoto, M.; Takada, S.; Yamashita, Y.; Ishikawa, S.; Fujiwara, S.; Watanabe, H.; Kurashina, K.; Hatanaka, H. Bando, M.; Ohno, S.; Ishikawa, Y.; Aburatani, H.; Niki, T.; Sohara, Y.; Sugiyama, Y.; Mano, H. Identification of the Transforming EML4-ALK Fusion Gene in Non-small-cell Lung Cancer. Nature 2007, 448(7153), 561–566.
   PubMed Web of Science ®Google Scholar
• Palmer, R.H.; Vernersson, E.; Grabbe, C.; Hallberg, B. Anaplastic Lymphoma Kinase: Signalling in Development and Disease. Biochem. J. 2009, 420(3), 345–361.
   PubMed Web of Science ®Google Scholar
• Hallberg, B.; Palmer, R.H. Mechanistic Insight into ALK Receptor Tyrosine Kinase in Human Cancer Biology. Nat. Rev. Cancer 2013, 13(10), 685–700.
   PubMed Web of Science ®Google Scholar
• Lindeman, N.I.; Cagle, P.T.; Beasley, M.B. Chitale, D.A.; Dacic, S.; Giaccone, G.; Jenkins, R.B.; Kwiatkowski, D.J.; Saldivar J.S.; Squire, J.; Thunnissen, E.; Ladanyi, M. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J. Thorac. Oncol. 2013, 8, 823–859.
   PubMed Web of Science ®Google Scholar
• Guggisberg, N.V. Clinicopathological Incidence, Significance, and Survival Outcomes of EML4-ALK Translocation in Lung Cancer. J. Thorac. Oncol. 2012, 7, 128.
   PubMed Web of Science ®Google Scholar
• Kim, H.R.; Shim, H.S.; Chung, J.H.; Lee, Y.J.; Hong, Y.K.; Rha, S.Y.; Kim, S.H.; Ha, S.J.; Kim, S.K.; Chung, K.Y.; Soo, R.; Kim, J.H.; Cho, B.C. Distinct Clinical Features and Outcomes in Never-smokers with Non small Cell Lung Cancer who Harbor EGFR or KRAS Mutations or ALK Rearrangement. Cancer 2010, 118, 729–739.
   Web of Science ®Google Scholar
• Lee, J.K.; Park, H.S.; Kim, D.W.; Kulig, K.; Kim, T.M.; Lee, S.H.; Jeon, Y.K.; Chung, D.H.; Heo, D.S.; Kim, W.H.; Ban, Y.J. Comparative Analyses of Overall Survival in Patients with Anaplastic Lymphoma Kinasepositive and Matched Wild-type Advanced Nonsmall Cell Lung Cancer. Cancer 2012, 118, 3579–3586.
   PubMed Web of Science ®Google Scholar
• Yang, P.; Kulig, K.; Boland, J.M.; Erickson-Johnson, M.R.; Oliveira, A.M.; Wampfler, J.; Jatoi, A.; Deschamps, C.; Marks, R.; Fortner, C.; Stoddard, S.; Nichols, F.; Molina, J.; Aubry, M.C.; Tang, H.; Yi, E.S. Worse Disease-free Survival in Never-smokers with ALK+ Lung Adenocarcinoma. J. Thorac. Oncol. 2012, 7, 90–97.
   PubMed Web of Science ®Google Scholar
• Martinez, P.; Hernández-Losa, J.; Montero, M.Á.; Cedrés, S.; Castellví, J.; Martinez-Marti, A.; Tallada, N.; Murtra-Garrell, N.; Navarro-Mendivill A.; Rodriguez-Freixinos, V.; Canela, M.; Ramon y Cajal, S.; Felip, E. Diagnostic Methods, Prevalence and Clinical Outcomes of Patients with ALK Positive Non-small Cell Lung Cancer. J. Thorac. Oncol. 2011, 6, 293.
   Google Scholar
• Solomon, B.; Varella-Garcia, M.; Camidge, D.R. ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer. J. Thorac. Oncol. 2009, 4, 1450–1454.
   PubMed Web of Science ®Google Scholar
• Shaw, A.T.; Kim, D.W.; Nakagawa, K.; Seto, T.; Crinó, L.; Ahn, M.J.; De Pas, T.; Besse, B.; Solomon, B.J.; Blackhall, F.; Wu, Y.L.; Thomas, M.; O'Byrne, K.J.; Moro-Sibilot, D.; Camidge, D.R.; Mok, T.; Hirsh, V.; Riely, G.J.; Iyer, S.; Tassell, V.; Polli, A.; Wilner, K.D.; Jänne, P.A. Crizotinib versus Chemotherapy in Advanced ALK-positive Lung Cancer. N. Engl. J. Med. 2013, 368(25), 2385–2394.
   PubMed Web of Science ®Google Scholar
• Camidge, D.R.; Bang, Y.J.; Kwak, E.L.; Iafrate, A.J.; Varella-Garcia, M.; Fox, S.B.; Riely, G.J.; Solomon, B.; Ou, S.H.; Kim, D.W.; Salgia, R.; Fidias, P.; Engelman, J.A.; Gandhi, L.; Jänne, P.A.; Costa, D.B.; Shapiro, G.I.; Lorusso, P.; Ruffner, K.; Stephenson, P.; Tang, Y.; Wilner, K.; Clark, J.W.; Shaw, A.T. Activity and Safety of Crizotinib in Patients with ALKpositive Non-small-cell Lung Cancer: Updated Results from a Phase 1 Study. Lancet Oncol. 2012, 13, 1011–1019.
   PubMed Web of Science ®Google Scholar
• Zwaenepoel, K.; Merkle, D.; Cabillic, F.; Berg, E.; Belaud-Rotureau, M.A.; Grazioli, V.; Herelle, O.; Hummel, M.; Le Calve, M.; Lenze, D.; Mende, S.; Pauwels, P.; Quilichini, B.; Repetti, E. Automation of ALK Gene Rearrangement Testing with Fluorescence in situ Hybridization (FISH): A Feasibility Study. Exp. Mol. Pathol. 2015, 98(1), 113–118.
   PubMed Web of Science ®Google Scholar
• Martin, V.; Bernasconi, B.; Merlo, E.; Balzarini, P.; Vermi, W.; Riva, A.; Chiaravalli, A.M.; Frattini, M.; Sahnane, N.; Facchetti, F.; Mazzucchelli, L.; Sessa, F.; Tibiletti, M.G. ALK Testing in Lung Adenocarcinoma: Technical Aspects to Improve FISH Evaluation in Daily Practice. J. Thorac. Oncol. 2015, 10(4), 595–602.
   PubMed Web of Science ®Google Scholar
• Ying, J.; Guo, L.; Qiu, T.; Shan, L.; Ling, Y.; Liu, X.; Lu, N. Diagnostic Value of a Novel Fully Automated Immunochemistry Assay for Detection of ALK Rearrangement in Primary Lung Adenocarcinoma. Ann. Oncol. 2013, 24(10), 2589–2593.
   PubMed Web of Science ®Google Scholar
• Wynes, M.W.; Sholl, L.M.; Dietel, M.; Schuuring, E.; Tsao, M.S.; Yatabe, Y.; Tubbs, R.R.; Hirsch, F.R. An International Interpretation Study using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and ALK FISH and between Evaluators. J. Thorac. Oncol. 2014, 9, 631–638.
   PubMed Web of Science ®Google Scholar
• Minca, E.C.; Portier, B.P.; Wang, Z.; Lanigan, C.; Farver, C.F.; Feng, Y.; Ma, P.C.; Arrossi, V.A.; Pennell, N.A.; Tubbs, R.R. ALK Status Testing in Non-small Cell Lung Carcinoma: Correlation between Ultrasensitive IHC and FISH. J. Mol. Diagn. 2013, 15(3), 341–346.
   PubMed Web of Science ®Google Scholar
• Martinez, P.; Hernández-Losa, J.; Montero, M.Á.; Cedrés, S.; Castellví, J.; Martinez-Marti, A.; Tallada, N.; Murtra-Garrell, N.; Navarro-Mendivill, A.; Rodriguez-Freixinos, V.; Canela, M.; Ramon y Cajal, S.; Felip, E. Fluorescence in situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive non-small Cell Lung Cancer Patients. PLoSOne 2013, 8, e52261.
   PubMed Web of Science ®Google Scholar
• Tantraworasin, A.; Lertprasertsuke, N.; Kongkarnka, S.; Euathrongchit, J.; Wannasopha, Y.; Saeteng, S. Retrospective Study of ALK Rearrangement and Clinicopathological Implications in Completely Resected Non-small Cell Lung Cancer Patients in Northern Thailand: Role of Screening with D5F3 Antibodies. Asian Pac. J. Cancer Prev. 2014, 15(7), 3057–3063.
   PubMedGoogle Scholar
• Minca, E.C.; Lanigan, C.P.; Reynolds, J.P.; Wang, Z.; Ma, P.C.; Cicenia, J.; Almeida, F.A.; Pennell, N.A.; Tubbs, R.R. ALK Status Testing in Non-small-cell Lung Carcinoma by FISH on ThinPrep Slides with Cytology Material. J. Thorac. Oncol. 2014, 9(4), 464–468.
   PubMed Web of Science ®Google Scholar
• Cabillic, F.; Gros, A.; Dugay, F.; Begueret, H.; Mesturoux, L.; Chiforeanu, D.C.; Dufrenot, L.; Jauffret, V.; Dachary, D.; Corre, R.; Lespagnol, A.; Soler, G.; Dagher J, Catros, V.; Le Calve, M.; Merlio, J.P.; Belaud-Rotureau, M.A. Parallel FISH and Immunohistochemical Studies of ALK Status in 3244 Non-small-cell Lung Cancers Reveal Major Discordances. J. Thorac. Oncol. 2014, 9(3), 295–306.
   PubMed Web of Science ®Google Scholar
• Shaw, A.T.; Yeap, B.Y.; Mino-Kenudson, M.; Digumarthy, S.R.; Costa, D.B.; Heist, R.S.; Solomon, B.; Stubbs, H.; Admane, S.; McDermott, U.; Settleman, J.; Kobayashi, S.; Mark, E.J.; Rodig, S.J.; Chirieac, L.R.; Kwak, E.L.; Lynch, T.J.; Iafrate, A.J. Clinical Features and Outcome of Patients with Non-small-cell Lung Cancer who Harbor EML4-ALK. J. Clin. Oncol. 2009, 27(26), 4247–4253.
   PubMed Web of Science ®Google Scholar
• Ohanna, S.M.; Brunnström, H.; Jabs, V.; Edlund, K.; Jirström, K.; Mindus, S.; la Fleur, L.; Pontén, F.; Mats, G.; Karlsson, K.; Koyi, H.; Brandén, E.; Botling, J.; Helenius, G.; Micke, P.; Svensson, M.A. Inconsistent Results in the Analysis of ALK Rearrangements in Non-small Cell Lung Cancer. BMC Cancer 2016, 16, 603.
   PubMed Web of Science ®Google Scholar
• Wang, J.; Cai, Y.; Dong, Y.; Nong, J.; Zhou, L.; Liu, G.; Su, D.; Li, X.; Wu, S.; Chen, X.; Qin, N.; Zeng, X.; Zhang, H.; Zhang, Z.; Zhang, S. Clinical Characteristics and Outcomes of Patients with Primary Lung Adenocarcinoma Harboring ALK Rearrangements Detected by FISH, IHC, and RT-PCR. PLoS One 2014, 9(7), e101551.
   PubMed Web of Science ®Google Scholar
• Zhang, Y.G.; Jin, M.L.; Li, L.; Zhao, H.Y.; Zeng, X.; Jiang, L.; Wei, P.; Diao, X.L.; Li, X.; Cao, Q.; Tian, X.X. Evaluation of ALK Rearrangement in Chinese Non-small Cell Lung Cancer using FISH, Immunohistochemistry, and Real-time Quantitative RT-PCR on Paraffin-embedded Tissues. PLoS One 2013, 8(5), e64821.
   PubMed Web of Science ®Google Scholar
• Cristina, T.; Niki, K.; Vicente, P.; Ana, G-C.; Rafael, R. Concordance of IHC, FISH and RT-PCR for EML4-ALK Rearrangements. Transl. Lung Cancer Res. 2014, 3(2), 70–74.
   PubMedGoogle Scholar
• Lee, J.A.; Bubendorf, L.; Stahel, R.; Peters, S. Testing for Anaplastic Lymphoma Kinase Rearrangement to Target Crizotinib Therapy: Oncology, Pathology and Health Economic Perspectives. Expert Rev Anticancer Ther. 2013, 13(5), 625–636.
   Google Scholar
• Akiba, J.; Kawahara, A.; Abe, H.; Azuma, K.; Yamaguchi, T.; Taira, T.; Fukumitsu, C.; Takase, Y.; Yasumoto, M.; Umeno, Y.; Todoroki, K.; Kurita, T.; Yamaguchi, R.; Kage, M.; Yano, H. Evaluation of Immunohistochemistry using Two Different Antibodies and Procedures for Primary Lung Adenocarcinoma Harboring Anaplastic Lymphoma Kinase Rearrangement. Oncol. Lett. 2014, 8(5), 2155–2159.
   PubMed Web of Science ®Google Scholar
• Taheri, D.; Zahavi, D.J.; Rodriguez, M.; Meliti, A.; Rezaee, N.; Yonescu, R.; Bernardo, F.; Ricardo, P.; Dolatkhah, S.; Ning, Y.; Bishop, J.; Netto, G.; Sharma, R. For Staining of ALK Protein, the Novel D5F3 Antibody Demonstrates Superior Overall Performance in Terms of Intensity and Extent of Staining in Comparison to the Currently used ALK1 Antibody. Virchows Arch. 2016, 469, 345–350.
   PubMed Web of Science ®Google Scholar
• Yi, E.S.; Boland, J.M.; Maleszewski, J.J.; Roden, A.C.; Oliveira, A.M.; Aubry, M.C.; Erickson-Johnson, M.R.; Caron, B.L.; Li, Y.; Tang, H.; Stoddard, S.; Wampfler, J.; Kulig, K.; Yang, P. Correlation of IHC and FISH for ALK Gene Rearrangement in Non-small Cell Lung Carcinoma: IHC Score Algorithm for FISH. J. Thorac. Oncol. 2011, 6(3), 459–465.
   PubMed Web of Science ®Google Scholar